Benign prostatic hyperplasia: a progressive disease of aging men

Emberton, Mark; Andriole, Gerald L.; Rosette, Jean de la; Djavan, Bob; Hoefner, K J; Navarrete, Remigio Vela; Nordling, Jørgen; Roehrborn, Claus G.; Schulman, Claude; Teillac, P.; Tubaro, Andrea; Nickel, J. Curtis

doi:10.1016/s0090-4295(02)02371-3

Cited by 188 publications

(111 citation statements)

References 22 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…10 The International Prostatic Symptom Score (IPSS) is used to assess the severity of LUTS in BPH patients. 11 In addition, measuring BWT by transabdominal ultrasound is a simple, non-invasive method to assess BOO in BPH patients. 12 In this study, we evaluated the BWT (as measured by transabdominal ultrasound) and IPSS of patients with BPH before and after treatment with tamsulosin.…”

Section: Introductionmentioning

confidence: 99%

Investigating the effect of tamsulosin on the measurement of bladder wall thickness and International Prostate Symptom Score in benign prostatic hyperplasia

Eghbali

Shayegan

Kianoush

2013

CUAJ

View full text Add to dashboard Cite

Introduction: According to previous studies, aging, gender, bladder volume and pathological states, such as bladder outflow obstruction, affect bladder wall thickness (BWT). The aim of this study was to evaluate the correlation between BWT and the International Prostatic Symptom Score (IPSS) in patients with benign prostatic hyperplasia (BPH) before and after tamsulosin treatment. Methods: In this study, 60 BPH patients were included. After obtaining informed consent, data were gathered using questionnaires to determine IPSS. After that, prostate-specific antigen was measured and a clinical examination, including a digital rectal examination, was performed for all patients. BWT was determined by transabdominal ultrasound. Finally, all patients were treated with tamsulosin (0.4 mg/day) for 2 months. After completing treatment, the IPSS and BWT were measured again and compared with the initial findings. Results: In total, 44 patients completed treatment. Patients aged 61.7 ± 9.2 years old. The mean ± standard deviation of IPSS and BWT were 14.6 ± 5.0 and 5.36 ± 1.28 mm before treatment, while they significantly (p < 0.0001) decreased to 8.2 ± 4.7 and 4.69 ± 1.23 mm, respectively, after treatment. Chi-square test showed that the decrease in BWT was significantly correlated with the improvement in IPSS (p = 0.002; r = 0.449). Conclusion: After treatment with tamsulosin, patients experienced a reduction in their BWT which was significantly correlated with improvement in their IPSS. We conclude that transabdominal evaluation of BWT could be included in the follow-up assessment in BPH.

show abstract

Section: Introductionmentioning

confidence: 99%

Investigating the effect of tamsulosin on the measurement of bladder wall thickness and International Prostate Symptom Score in benign prostatic hyperplasia

Eghbali

Shayegan

Kianoush

2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…3 Dihydrotestosterone (DHT), the primary androgen responsible for prostate growth, is synthesized from testosterone by type 1 and type 2 5a-reductase (5AR), both of which are expressed and active in the prostate. [4][5][6] There is a wealth of evidence for a key role of DHT in the development and progression of BPH.…”

Section: Introductionmentioning

confidence: 99%

The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia

Wurzel

Ray

Major-Walker

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The dual 5a-reductase inhibitor, dutasteride has been shown to suppress serum dihydrotestosterone (DHT) by 490%. In the present study, the effect of dutasteride 0.5 mg/day on intraprostatic DHT levels was investigated. In this multicenter, double-blind trial, 43 men with benign prostatic hyperplasia (BPH) scheduled to undergo transurethral resection of the prostate (TURP) were randomized to receive dutasteride, 0.5 mg/day or placebo for 3 months before surgery. Intraprostatic DHT, testosterone and dutasteride levels were determined at the time of TURP. Changes in serum DHT and testosterone from baseline, and both serum and intraprostatic dutasteride levels at the time of TURP were also assessed. Dutasteride reduced intraprostatic DHT by 94% relative to placebo (Po0.001); the adjusted mean intraprostatic DHT concentration was 3.23 and 0.209 ng/g in the placebo and dutasteride groups, respectively. In the dutasteride group, serum DHT was reduced from baseline by 93% at month 3, a significantly greater reduction (Po0.001) than the 15% decrease observed in the placebo group. There was a reciprocal increase in intraprostatic testosterone but the level of intraprostatic testosterone in the dutasteride group tended to be lower than the intraprostatic DHT level in the placebo group (P ¼ 0.06). Significant intraprostatic DHT suppression was achieved in all subjects who received dutasteride, regardless of the level of intraprostatic dutasteride. There was a strong positive correlation between serum and intraprostatic dutasteride concentrations (R 2 ¼ 0.73). After 3 months of treatment, dutasteride 0.5 mg/day provided near-complete suppression of both intraprostatic and serum DHT in men with BPH.

show abstract

“…Furthermore, EP is a progressive disease in many men, characterized by increasing prostatic enlargement, worsening LUTS, and an increased risk of acute urinary retention (AUR) and EP-related surgical intervention. [1][2][3][4] Understanding the likelihood of disease progression and the impact of EP and its associated symptoms on individual men is a crucial component of disease management, particularly as symptoms are incongruous and may be weighted differently by patients and doctors. 5 Despite a number of regional population-based studies, few published data are available from US national surveys.…”

Section: Introductionmentioning

confidence: 99%

Enlarged prostate: A landmark national survey of its prevalence and impact on US men and their partners

Roehrborn

Marks

Harkaway

2005

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

This questionnaire-based survey evaluated the frequency and severity of lower urinary tract symptoms (LUTS) and the prevalence of enlarged prostate (EP) diagnosis and its impact on quality of life and spousal relationships among 41000 American men aged 450 years. A quarter of men suffered moderate to severe LUTS and 55% of those consulting a doctor had EP. EP negatively affected patient quality of life and caused relationship strain with spouses. These findings confirm that LUTS and EP are prevalent in the US population, affecting both patient and spouse, and may help in developing management strategies for EP.

show abstract

Benign prostatic hyperplasia: a progressive disease of aging men

Cited by 188 publications

References 22 publications

Investigating the effect of tamsulosin on the measurement of bladder wall thickness and International Prostate Symptom Score in benign prostatic hyperplasia

Investigating the effect of tamsulosin on the measurement of bladder wall thickness and International Prostate Symptom Score in benign prostatic hyperplasia

The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia

Enlarged prostate: A landmark national survey of its prevalence and impact on US men and their partners

Contact Info

Product

Resources

About